Related Experiment Video
Updated: Jun 1, 2026
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium
Sachiko Kanki1, Vincent F M Segers, Weitao Wu
1Harvard Stem Cell Institute, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA.
Insights
A protease-resistant form of Stromal cell-derived factor-1 (SDF-1), called SSDF-1(S4V), significantly improves heart function and blood vessel growth after myocardial infarction. This offers a promising clinical approach to prevent heart failure following ischemic injury.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Biochemistry
Background:
- Stromal cell-derived factor-1 (SDF-1) attracts stem cells and may enhance ventricular function post-infarction.
- Proteases like matrix metalloproteinase-2 (MMP-2) and dipeptidylpeptidase-4 (DPP-4) degrade SDF-1 in injured tissues.
- Understanding SDF-1 stability is crucial for its therapeutic application in cardiac injury.
Purpose of the Study:
- To investigate the biodistribution and functional effects of SDF-1 in a rat model of ischemia/reperfusion injury.
- To evaluate a bioengineered, protease-resistant SDF-1 variant (SSDF-1(S4V)) for enhanced cardioprotection.
- To assess the therapeutic potential of SSDF-1(S4V) in improving cardiac function and angiogenesis after myocardial infarction.
Main Methods:
- Rats with induced ischemia/reperfusion injury received intracoronary injections of radiolabeled SDF-1.
- Biodistribution of SDF-1 in ischemic myocardium was assessed.
- Mass spectrometry and Western blot analyses were used to identify SDF-1 cleavage by DPP-4.
- The stability and efficacy of the engineered SSDF-1(S4V) were compared to wild-type SDF-1.
Main Results:
- Radiolabeled SDF-1 selectively accumulated in ischemic myocardium, independent of its receptor CXCR4.
- SDF-1 was found to be cleaved by DPP-4 in plasma and cardiac tissue.
- The engineered SSDF-1(S4V) demonstrated significantly higher stability and greater cardioprotective potency than wild-type SDF-1.
- SSDF-1(S4V) administration improved cardiac function even after a 3-hour ischemic period.
Conclusions:
- Protease-resistant SSDF-1(S4V) administration post-myocardial infarction dramatically improves angiogenesis and ventricular function.
- A single dose of SSDF-1(S4V) provides significant benefits even when administered 3 hours after ischemia onset.
- SSDF-1(S4V) represents a simple and clinically feasible strategy for preventing heart failure after heart attack.
Background:
Stromal cell-derived factor-1 (SDF-1) is a chemoattractant of stem/progenitor cells, and several studies have shown that SDF-1 may improve ventricular function after infarction. SDF-1 is cleaved by proteases including matrix metalloproteinase-2 (MMP-2) and CD26/dipeptidylpeptidase-4 (DPP-4), which are activated in injured tissues.
Methods And Results:
We investigated the biodistribution and functional roles of SDF-1 in experimental ischemia/reperfusion injury in rats. Radiolabeled SDF-1 given by intracoronary injection was selectively concentrated in ischemic myocardium. The enhanced uptake of SDF-1 in ischemic myocardium was not mediated by its receptor, CXCR4. Mass spectrometry and Western analyses showed that SDF-1 was cleaved by DPP-4 in plasma and myocardium, whereas a bioengineered MMP-2/DPP-4-resistant form of SDF-1, SSDF-1(S4V), was highly stable. A single dose of SSDF-1(S4V) exhibited greater potency for cardioprotection than wild-type SDF-1. SSDF-1(S4V) improved cardiac function in rats even after a 3-hour ischemic period.
Conclusions:
These results show that a single dose of protease-resistant SSDF-1(S4V) after myocardial infarction leads to dramatic improvement in angiogenesis and ventricular function even 3 hours after the onset of ischemia, revealing a simple, clinically feasible approach to prevention of heart failure.
